SEC Form 4 · accession 0001209191-16-114857
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard Levy
Officer — Chief Medical Officer
Period of report
Apr 18, 2016
Accepted (ET)
Apr 19, 2016 · 4:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $1.52 | Apr 18, 2016 | A | 100,000 | A | — | Apr 18, 2026 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1These stock options are awarded under the 2016 Inducement Stock Incentive Plan.
- F2Options vest and are exercisable as to 25% of the underlying grant one year after the vesting commencement date of April 18, 2016 and in equal monthly installments thereafter for three additional years, subject to acceleration in certain circumstances.